查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1595148

聚乙二醇化蛋白质市场：依产品类型、蛋白质类型、适应症、最终用户 - 2025-2030 年全球预测

PEGylated Proteins Market by Product (PEGylation Kits, PEGylation Reagents, Services), Protein Type (Colony-Stimulating Factor, Erythropoietin, Interferons), Indication, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年聚乙二醇化蛋白市值为14.3亿美元，预计到2024年将达到15.7亿美元，复合年增长率为10.14%，到2030年将达到28.1亿美元。

聚乙二醇化蛋白质是与聚乙二醇 (PEG) 分子共用连接的治疗性蛋白质，可增强药理特性，例如增加溶解度、稳定性和免疫抗原性。这些蛋白质的需求是因为它们广泛用于治疗癌症、肝炎和多发性硬化症等慢性和严重。最终用途主要包括製药和生物技术行业，其中人口老化和慢性病的增加正在迅速增加对先进药物输送系统的需求。根据市场洞察，不断增加的研发活动、有利的法规结构以及蛋白质疗法的技术进步正在推动强劲的成长轨迹。生技药品的发展和个人化医疗的兴起也是关键的成长要素。

主要市场统计
基准年[2023] 14.3亿美元
预测年份 [2024] 15.7亿美元
预测年份 [2030] 28.1亿美元
复合年增长率（%） 10.14%

最近的潜在商机在于不断扩大的生物製药行业和不断发展的医疗基础设施的新兴市场。公司应专注于创新下一代聚乙二醇化技术，以提供有针对性的递送并减少副作用。与学术机构合作进行尖端研发可以进一步增强您的市场地位。然而，高製造成本和复杂的製造流程会阻碍价格竞争力。此外，监管环境要求严格，核准流程严格，需要投入大量时间和资源。

最佳创新领域包括开发可提高效率和特异性的新型聚乙二醇化技术，例如位点特异性缀合方法。探索提高聚乙二醇化功效和生物分解性的替代生物聚合物可以提供竞争优势。市场的本质是高度动态和竞争的，对专有技术进行大量投资并强调策略伙伴关係关係。企业应优先加强研发能力和促进协作，以保持竞争优势。透过解决现有挑战并利用技术进步，企业可以释放这个前景广阔的行业的巨大成长潜力。

市场动态：揭示快速发展的聚乙二醇化蛋白质市场的关键市场洞察

供需的动态交互作用正在改变聚乙二醇化蛋白质市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 人口中慢性病盛行率上升
    • 加大药品研发项目的投资
    • 各国医疗基础设施现代化
  • 市场限制因素
    • 聚乙二醇化过程相关的高成本
  • 市场机会
    • 越来越重视生物技术和生物分子工程
    • 聚乙二醇化在标靶特异性药物传递的潜力
  • 市场挑战
    • 漫长而严格的医药品认证过程

波特五力：驾驭聚乙二醇化蛋白质市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解聚乙二醇化蛋白质市场的外部影响

外部宏观环境因素在塑造聚乙二醇化蛋白质市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解聚乙二醇化蛋白质市场的竞争格局

聚乙二醇化蛋白质市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵聚乙二醇化蛋白市场供应商的绩效评估

FPNV定位矩阵是评估聚乙二醇化蛋白质市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了聚乙二醇化蛋白质市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，聚乙二醇化蛋白市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 人口中慢性病盛行率不断上升
      • 加大药品研发项目的投资
      • 实现整个经济领域医疗基础设施的现代化
    • 抑制因素
      • 聚乙二醇化过程相关的高成本
    • 机会
      • 强调生物技术与生物分子工程
      • 聚乙二醇化在标靶特异性药物传递的潜力
    • 任务
      • 严格而漫长的医药品认证过程
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 聚乙二醇化蛋白市场：副产品

  • 聚乙二醇化试剂套件
  • 聚乙二醇化试剂
    • 生物功能聚乙二醇
    • 支链聚乙二醇
    • 单官能线性 PEG
    • 多臂聚乙二醇
  • 服务

第 7 章按蛋白质类型分類的聚乙二醇化蛋白质市场

  • 集落刺激因子
  • 促红血球生成素
  • 干扰素
  • 单株抗体
  • 重组因子VII

第 8 章 聚乙二醇化蛋白市场（按适应症）

  • 自体免疫疾病
  • 癌症
  • 胃肠道疾病
  • 血友病
  • 肝炎
  • 多发性硬化症

第 9 章 聚乙二醇化蛋白质市场：依最终用户分类

  • 学术研究所
  • CRO
  • 製药和生物製药公司

第10章美洲聚乙二醇化蛋白市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区聚乙二醇化蛋白市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲的聚乙二醇化蛋白质市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
  • 战略分析和建议

公司名单

  • Abcam PLC
  • Aurigene Pharmaceutical Services Limited
  • Biogen Inc.
  • BioMarin
  • Biomatrik Inc.
  • Celares GmbH
  • Creative PEGWorks
  • Enzon Pharmaceuticals, Inc.
  • Exelead
  • F. Hoffmann-La Roche Ltd.
  • Horizon Therapeutics PLC
  • Iris Biotech GmbH
  • JenKem Technology USA Inc.
  • Laysan Bio, Inc.
  • Ligand Pharmaceuticals Inc
  • Merck KGaA
  • NOF CORPORATION
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Profacgen
  • Quanta BioDesign Ltd
  • QuiaPEG Pharmaceuticals Holding AB
  • Takeda Pharmaceuticals Company Limited
  • Thermo Fisher Scientific Inc.
  • UCB SA
Product Code: MRR-69324464D0F0

The PEGylated Proteins Market was valued at USD 1.43 billion in 2023, expected to reach USD 1.57 billion in 2024, and is projected to grow at a CAGR of 10.14%, to USD 2.81 billion by 2030.

PEGylated proteins are therapeutic proteins that have been covalently bonded with polyethylene glycol (PEG) molecules to enhance their pharmacological properties, such as increased solubility, stability, and reduced immunogenicity. The necessity of these proteins stems from their wide-ranging applications in treating chronic and severe diseases like cancer, hepatitis, and multiple sclerosis. The end-use scope primarily includes pharmaceutical and biotechnology industries, where the demand for advanced drug delivery systems is burgeoning due to an aging population and increased prevalence of chronic diseases. Market insights indicate a robust growth trajectory driven by increasing R&D activities, favorable regulatory frameworks, and technological advancements in protein-based therapeutics. The rise in biologics development and personalized medicine also represents key growth factors.

KEY MARKET STATISTICS
Base Year [2023] USD 1.43 billion
Estimated Year [2024] USD 1.57 billion
Forecast Year [2030] USD 2.81 billion
CAGR (%) 10.14%

Recent potential opportunities lie in the expanding biopharmaceutical sector and emerging markets where healthcare infrastructures are evolving. Companies should focus on innovating next-generation PEGylation technologies that offer targeted delivery and reduced side effects. Collaborations with academic institutions for cutting-edge research and development can further enhance market positioning. However, limitations include high production costs and complex manufacturing processes that may stifle price competitiveness. Additionally, the regulatory landscape can be challenging, with stringent approval processes that require substantial time and resource investments.

Best areas for innovation include the development of novel PEGylation techniques that improve efficiency and specificity, such as site-specific conjugation methods. Research in alternative biopolymers that enhance PEGylation efficacy and biodegradability may offer a competitive edge. The nature of the market is highly dynamic and competitive, with significant investments in proprietary technologies and a focus on strategic partnerships. Companies should prioritize enhancing their R&D capabilities and fostering collaborations to maintain a competitive advantage. By addressing existing challenges and capitalizing on technological advancements, businesses can unlock significant growth potential in this promising sector.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving PEGylated Proteins Market

The PEGylated Proteins Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of chronic diseases among population
    • Growing investments in pharmaceutical research and development programs
    • Modernization of healthcare infrastructure across economies
  • Market Restraints
    • High costs associated with PEGylation process
  • Market Opportunities
    • Higher emphasis on biotechnology and biomolecular engineering
    • Potential of PEGylation in target specific drug delivery
  • Market Challenges
    • Time consuming stringent drug approval processes

Porter's Five Forces: A Strategic Tool for Navigating the PEGylated Proteins Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the PEGylated Proteins Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the PEGylated Proteins Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the PEGylated Proteins Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the PEGylated Proteins Market

A detailed market share analysis in the PEGylated Proteins Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the PEGylated Proteins Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the PEGylated Proteins Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the PEGylated Proteins Market

A strategic analysis of the PEGylated Proteins Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the PEGylated Proteins Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, Aurigene Pharmaceutical Services Limited, Biogen Inc., BioMarin, Biomatrik Inc., Celares GmbH, Creative PEGWorks, Enzon Pharmaceuticals, Inc., Exelead, F. Hoffmann-La Roche Ltd., Horizon Therapeutics PLC, Iris Biotech GmbH, JenKem Technology USA Inc., Laysan Bio, Inc., Ligand Pharmaceuticals Inc, Merck KGaA, NOF CORPORATION, Novo Nordisk A/S, Pfizer Inc., Profacgen, Quanta BioDesign Ltd, QuiaPEG Pharmaceuticals Holding AB, Takeda Pharmaceuticals Company Limited, Thermo Fisher Scientific Inc., and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the PEGylated Proteins Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across PEGylation Kits, PEGylation Reagents, and Services. The PEGylation Reagents is further studied across Biofunctional PEGs, Branched PEGs, Monofunctional Linear PEGs, and Multi-Arm PEGs.
  • Based on Protein Type, market is studied across Colony-Stimulating Factor, Erythropoietin, Interferons, mAbs, and Recombinant Factor VII.
  • Based on Indication, market is studied across Autoimmune Diseases, Cancer, Gastrointestinal Disorders, Hemophilia, Hepatitis, and Multiple Sclerosis.
  • Based on End-User, market is studied across Academic & Research Institutes, CROs, and Pharmaceutical & Biopharmaceutical Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases among population
      • 5.1.1.2. Growing investments in pharmaceutical research and development programs
      • 5.1.1.3. Modernization of healthcare infrastructure across economies
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with PEGylation process
    • 5.1.3. Opportunities
      • 5.1.3.1. Higher emphasis on biotechnology and biomolecular engineering
      • 5.1.3.2. Potential of PEGylation in target specific drug delivery
    • 5.1.4. Challenges
      • 5.1.4.1. Time consuming stringent drug approval processes
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. PEGylated Proteins Market, by Product

  • 6.1. Introduction
  • 6.2. PEGylation Kits
  • 6.3. PEGylation Reagents
    • 6.3.1. Biofunctional PEGs
    • 6.3.2. Branched PEGs
    • 6.3.3. Monofunctional Linear PEGs
    • 6.3.4. Multi-Arm PEGs
  • 6.4. Services

7. PEGylated Proteins Market, by Protein Type

  • 7.1. Introduction
  • 7.2. Colony-Stimulating Factor
  • 7.3. Erythropoietin
  • 7.4. Interferons
  • 7.5. mAbs
  • 7.6. Recombinant Factor VII

8. PEGylated Proteins Market, by Indication

  • 8.1. Introduction
  • 8.2. Autoimmune Diseases
  • 8.3. Cancer
  • 8.4. Gastrointestinal Disorders
  • 8.5. Hemophilia
  • 8.6. Hepatitis
  • 8.7. Multiple Sclerosis

9. PEGylated Proteins Market, by End-User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. CROs
  • 9.4. Pharmaceutical & Biopharmaceutical Companies

10. Americas PEGylated Proteins Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific PEGylated Proteins Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa PEGylated Proteins Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abcam PLC
  • 2. Aurigene Pharmaceutical Services Limited
  • 3. Biogen Inc.
  • 4. BioMarin
  • 5. Biomatrik Inc.
  • 6. Celares GmbH
  • 7. Creative PEGWorks
  • 8. Enzon Pharmaceuticals, Inc.
  • 9. Exelead
  • 10. F. Hoffmann-La Roche Ltd.
  • 11. Horizon Therapeutics PLC
  • 12. Iris Biotech GmbH
  • 13. JenKem Technology USA Inc.
  • 14. Laysan Bio, Inc.
  • 15. Ligand Pharmaceuticals Inc
  • 16. Merck KGaA
  • 17. NOF CORPORATION
  • 18. Novo Nordisk A/S
  • 19. Pfizer Inc.
  • 20. Profacgen
  • 21. Quanta BioDesign Ltd
  • 22. QuiaPEG Pharmaceuticals Holding AB
  • 23. Takeda Pharmaceuticals Company Limited
  • 24. Thermo Fisher Scientific Inc.
  • 25. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. PEGYLATED PROTEINS MARKET RESEARCH PROCESS
  • FIGURE 2. PEGYLATED PROTEINS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PEGYLATED PROTEINS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PEGYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS PEGYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES PEGYLATED PROTEINS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES PEGYLATED PROTEINS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PEGYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC PEGYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PEGYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PEGYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. PEGYLATED PROTEINS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. PEGYLATED PROTEINS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PEGYLATED PROTEINS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PEGYLATED PROTEINS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PEGYLATED PROTEINS MARKET DYNAMICS
  • TABLE 7. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY BIOFUNCTIONAL PEGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY BRANCHED PEGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY MONOFUNCTIONAL LINEAR PEGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY MULTI-ARM PEGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY COLONY-STIMULATING FACTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY MABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY RECOMBINANT FACTOR VII, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY CROS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL PEGYLATED PROTEINS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS PEGYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES PEGYLATED PROTEINS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC PEGYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. MALAYSIA PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. PHILIPPINES PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. SINGAPORE PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. SOUTH KOREA PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. TAIWAN PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. THAILAND PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. VIETNAM PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA PEGYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. DENMARK PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. EGYPT PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. FINLAND PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. FRANCE PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. GERMANY PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. ISRAEL PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. ITALY PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. NETHERLANDS PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. NIGERIA PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. NORWAY PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. POLAND PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 196. QATAR PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 201. RUSSIA PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 206. SAUDI ARABIA PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 216. SPAIN PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 221. SWEDEN PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 226. SWITZERLAND PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 231. TURKEY PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED ARAB EMIRATES PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM PEGYLATED PROTEINS MARKET SIZE, BY PEGYLATION REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM PEGYLATED PROTEINS MARKET SIZE, BY PROTEIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM PEGYLATED PROTEINS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM PEGYLATED PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 242. PEGYLATED PROTEINS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 243. PEGYLATED PROTEINS MARKET, FPNV POSITIONING MATRIX, 2023